Unterschiede durch sozioökomische Benachteiligung, genetischen Hintergrund und Geschlecht bei Tumorerkrankungen

Die Evidenz, dass individuelle biologische und soziale Faktoren differente Symptome und Verläufe von Tumorerkrankungen bedingen, ist durch die COVID-19-Pandemie noch deutlicher geworden. Tumorepidemiologische und präzisionsonkologische Untersuchungen zeigen, dass Geschlechtsdifferenzen in Tumorstudien bestehen, bestimmte Gruppen genetischer Herkunft unterrepräsentiert sind und insgesamt Studienpopulationen unausgewogen bleiben. Insbesondere benachteiligte Bevölkerungsgruppen werden selten darin abgebildet. Der Beitrag bietet eine aktuelle Übersicht über diversitätsspezifische Aspekte in der Onkologie, die zukünftig verbessert werden sollten.

Abstract

Malignant tumor diseases constitute the 2^nd most common cause of death and due to our extended life expectancy cancer per se has substantially increased, being highly prevalent after cardiovascular diseases. Evidence also generated from the COVID-19 pandemic, that defined gender differences exist in symptom and disease courses, and have advocated the need to assess gender, ethnic/racial and minority differences in cancer care and treatment more meticulously. It is becoming increasingly evident that in novel cancer care/precision oncology, representation of minorities, elderly and frail patients in clinical trials remains largely unbalanced, thus distribution of cancer success is iniquitous. This article focusses on these aspects and suggests solutions, how this can be improved.

Schlüsselwörter

Tumorerkrankungen - ethnische - Geschlechts- und Minoritäten-Differenzen

Key words

cancer treatment - racial/ethnic- - gender-, minority-differences

Publikationsverlauf

Artikel online veröffentlicht:
24. April 2023

• Literatur

• 1 Dimopoulos MA, Moreau P, Terpos E. et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(†). Ann Oncol 2021; 32: 309-322
• 2 Crenshaw K. Demarginalizing the Intersection of Race and Sex: A Black Feminist Critique of Antidiscrimination Doctrine, Feminist Theory and Antiracist Politics. University of Chicago Legal Forum. Vol. 1989: Iss. 1, Article 8.. Im Internet (Stand: 06.11.2022): http://chicagounbound.uchicago.edu/uclf/vol1989/iss1/8
• 3 Casey M, Odhiambo L, Aggarwal N. et al. Are Pivotal Clinical Trials for Drugs Approved for Leukemias and Multiple Myeloma Representative of the Population at Risk?. J Clin Oncol 2022; 40: JCO2200504
• 4 Asher S, Kazantzi A, Dekaj F. et al. Under-representation of ethnic minorities in early phase clinical trials for multiple myeloma. Haematologica 2022;
• 5 Zeilinger EL, Lubowitzki S, Unseld M. et al. The impact of COVID-19 on cancer care of outpatients with low socioeconomic status. Int J Cancer 2022; 151: 77-82
• 6 Kroll LE, Schumann M, Hoebel J. et al. Regionale Unterschiede in der Gesundheit – Entwicklung eines sozioökonomischen Deprivationsindex für Deutschland. J Health Monitor 2017; 2: 103-120
• 7 Maier W. Indizes Multipler Deprivation zur Analyse regionaler Gesundheitsunterschiede in Deutschland. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2017; 60: 1403-1412
• 8 Berger J, Engelhardt M, Möller MD. et al. Sozioökonomische Benachteiligung als Risikofaktor für Krebserkrankungen – „closing the care gap“. Forum 2022; 37: 382-386
• 9 Hoebel J, Kroll LE, Fiebig J. et al. Socioeconomic Inequalities in Total and Site-Specific Cancer Incidence in Germany: A Population-Based Registry Study. Front Oncol 2018; 8: 402
• 10 Schmidt B, Debold E, Frank M. et al. Socioeconomic Position is Positively Associated with Monoclonal Gammopathy of Undetermined Significance in a Population-based Cohort Study. Ann Hematol 2019; 98: 2761-2767
• 11 Tetzlaff F, Hoebel J, Epping J. et al. Time Trends and Income Inequalities in Cancer Incidence and Cancer-Free Life Expectancy – a Cancer Site-Specific Analysis of German Health Insurance Data. Front Oncol 2022; 12: 827028
• 12 Möller MD, Ihorst G, Pahl A. et al. Physical activity is associated with less comorbidity, better treatment tolerance and improved response in patients with multiple myeloma undergoing stem cell transplantation. J Geriatr Oncol 2021; 12: 521-530
• 13 Finke I, Behrens G, Maier W. et al. Small-area analysis on socioeconomic inequalities in cancer survival for 25 cancer sites in Germany. Int J Cancer 2021; 149: 561-572
• 14 Whitehead M. The Concepts and Principles of Equity and Health. Int J Health Serv 1992; 22: 429-445
• 15 Whitehead M, Dahlgren Gr. WHO Regional Office for Europe. Levelling up (part 1): a discussion paper on concepts and principles for tackling social inequities in health/by Margaret Whitehead and Göran Dahlgren. Copenhagen: WHO Regional Office for Europe; 2006 Im Internet (Stand: 06.11.2022): https://apps.who.int/iris/handle/10665/107790
• 16 Hoebel J, Richter M, Lampert T. Social status and participation in health checks in men and women in Germany: results from the German Health Update (GEDA), 2009 and 2010. Dtsch Ärztebl Int 2013; 110: 679-685
• 17 Menvielle G, Boshuizen H, Kunst AE. et al. The Role of Smoking and Diet in Explaining Educational Inequalities in Lung Cancer Incidence. J Natl Cancer Inst 2009; 101: 321-330
• 18 Menvielle G, Luce D, Goldberg P. et al. Smoking, alcohol drinking, occupational exposures and social inequalities in hypopharyngeal and laryngeal cancer. Int J Epidemiol 2004; 33: 799-806
• 19 Teng AM, Blakely T, Baker MG. et al. The contribution of Helicobacter pylori to excess gastric cancer in Indigenous and Pacific men: a birth cohort estimate. Gastric Cancer 2017; 20: 752-755
• 20 WHO Regional Office for Europe. WHO European Childhood Obesity Surveillance Initiative (COSI) Report on the fourth round of data collection, 2015–2017. Copenhagen: WHO Regional Office for Europe 2021; 2021 Licence: CC BY-NC-SA 3.0 IGO. Im Internet (Stand: 06.11.2022): https://apps.who.int/iris/bitstream/handle/10665/341189/WHO-EURO-2021-2495-42251-58349-eng.pdf
• 21 Smith CJ, Ambs S, Landgren O. Biological determinants of health disparities in multiple myeloma. Blood Cancer J 2018; 8: 85
• 22 Dong J, Garacci Z, Buradagunta CS. et al. Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study. Blood Cancer J 2022; 12: 34
• 23 Richardson PG, Jacobus SJ, Weller EA. et al. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med 2022; 387: 132-147
• 24 Attal M, Lauwers-Cances V, Hulin C. et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med 2017; 376: 1311-1320
• 25 Bhatnagar B, Kohlschmidt J, Mrózek K. et al. Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia. Cancer Discov 2021; 11: 626-637
• 26 Smith-Graziani D, Flowers CR. Understanding and Addressing Disparities in Patients With Hematologic Malignancies: Approaches for Clinicians. Am Soc Clin Oncol Educ Book 2021; 41: 1-7
• 27 Staron A, Connors LH, Zheng L. et al. Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities. Blood Cancer J 2020; 10: 118
• 28 Brioli A, Nägler TM, Yomade O. et al. Sex-disaggregated analysis of biology, treatment tolerability and outcome of Multiple Myeloma in a German cohort. Oncol Res Treat 2022; 45: 494-503
• 29 Bird S, Cairns D, Menzies T. et al. Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial. Clin Lymphoma Myeloma Leuk 2021; 21: 667-675
• 30 Wagner AD, Grothey A, Andre T. et al. Sex and adverse events of adjuvant chemotherapy in colon cancer: an analysis of 34,640 patients in the ACCENT database. J Natl Cancer Inst 2021; 113: 400-407
• 31 Blijlevens N, Schwenkglenks M, Bacon P. et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol 2008; 26: 1519-1525
• 32 Mueller F, Büchel B, Köberle D. et al. Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. Cancer Chemother Pharmacol 2013; 71: 361-370
• 33 Heinrich K, Modest DP, Ricard I. et al. Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110). Eur J Cancer 2021; 147: 128-139
• 34 Brady E, Nielsen MW, Andersen JP. et al. Lack of consideration of sex and gender in COVID-19 clinical studies. Nat Commun 2021; 12: 4015
• 35 Castañeda-Avila MA, Jesdale BM, Beccia A. et al. Differences in survival among multiple myeloma patients in the United States SEER population by neighborhood socioeconomic status and race/ethnicity. Cancer Causes Control 2021; 32: 1021-1028
• 36 Sittner M. Gendermedizin: Zeit für gute Neuigkeiten. Dtsch Ärztebl Int 2022; 119: A-324
• 37 Duma N, Azam T, Riaz IB. et al Representation of Minorities and Elderly Patients in Multiple Myeloma Clinical Trials. Oncologist 2018; 23: 1076-1078
• 38 Ailawadhi S, Jacobus S, Sexton R. et al Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J 2018; 8: 67
• 39 Asher S, Kazantzi A, Dekaj F. et al Under-representation of ethnic minorities in early phase clinical trials for multiple myeloma. Haematologica 2022;
• 40 Casey M, Odhiambo L, Aggarwal N. et al Are Pivotal Clinical Trials for Drugs Approved for Leukemias and Multiple Myeloma Representative of the Population at Risk?. J Clin Oncol 2022; JCO2200504
• 41 Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004; 291: 2720-2726
• 42 Grant SR, Lin TA, Miller AB. et al Racial and Ethnic Disparities Among Participants in US-Based Phase 3 Randomized Cancer Clinical Trials. JNCI Cancer Spectr 2020; 4: pkaa060
• 43 Loree JM, Anand S, Dasari A. et al Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018. JAMA Oncol 2019; 5: e191870
• 44 Viana JN, Edney S, Gondalia S. et al Trends and gaps in precision health research: a scoping review. BMJ Open 2021; 11: e056938
• 45 Giri VN, Shimada A, Leader AE. Predictors of Population Awareness of Cancer Genetic Tests: Implications for Enhancing Equity in Engaging in Cancer Prevention and Precision Medicine. JCO Precis Oncol 2021; 5: PO.21.00231
• 46 Wojcik GL, Graff M, Nishimura KK. et al. Genetic analyses of diverse populations improves discovery for complex traits. Nature 2019; 570: 514-518
• 47 Aldrighetti CM, Niemierko A, Van Allen E. et al Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies. JAMA Netw Open 2021; 4: e2133205
• 48 Nazha B, Mishra M, Pentz R. et al Enrollment of Racial Minorities in Clinical Trials: Old Problem Assumes New Urgency in the Age of Immunotherapy. Am Soc Clin Oncol Educ Book 2019; 39: 3-10
• 49 Nwankwo Jr EC, Hendrix C, Pollard K. et al Epidemiologic disparities in colon cancer screening and adherence during the COVID-19 pandemic: a retrospective cohort analysis. Int J Colorectal Dis 2022; 37: 849-854
• 50 Kalvelage B. Klassenmedizin: Plädoyer für eine soziale Reformation der Heilkunst. Berlin: Springer; 2014
• 51 Helmert U, Schorb F. Die Bedeutung verhaltensbezogener Faktoren im Kontext der sozialen Ungleichheit der Gesundheit. In: Richter M, Hurrelmann K. Hrsg. Gesundheitliche Ungleichheit: Grundlagen, Probleme, Perspektiven. Wiesbaden: VS Verlag für Sozialwissenschaften; 2009: 133-148